Bioprocess Control Specialist Focuses on Single-Use Sensors
Lab Automation through Single-Use Sensors and Monitors
Lonza Upgrades Live-Cell Imaging System
For Obtaining Better Cell-Culture Analyses
Antibody Characterization Balances Rigor and Reason
Emphasizes a Combination of Antibody-Dependent and -Independent Testing Methods
Cancer Immunotherapy Spurs Work on Better Animal Models
GEN Spoke to Several Researchers on Advances in Engineered Animal Models Used to Study Novel Cancer Im-munotherapies
<i>Prometheus v. Mayo</i>
During oral arguments before the U.S. Supreme Court in a case being watched closely by molecular diagnostics companies, justices repeatedly asked lawyers for Prometheus Laboratories and Mayo Collaborative Services for direction on the key question wrought by the patent litigation: When does a claim involving diagnostic and treatment-related chemical observations, among examples of natural phenomena, meet the threshold for patent eligibility?
The justices didn’t get the clear answer they sought. Now it will be up to the nine to answer the question as they decide Prometheus v. Mayo by looking to the law to determine what intellectual property molecular diagnostics companies can and cannot patent. What do you think?